Short Chain Fatty Acids in Neurodegeneration

📖 Wiki Page

mechanism2335 wordssynced 2026-04-02

Short Chain Fatty Acids in Neurodegeneration

Overview

Short chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate, are produced by gut microbiota through fermentation of dietary fiber. These microbial metabolites have emerged as critical signaling molecules linking gut health to brain function in what is now recognized as the gut-microbiota-brain axis["1"](https://pubmed.ncbi.nlm.nih.gov/31085246/). SCFAs exert profound effects on neuroinflammation, synaptic plasticity, blood-brain barrier integrity, and neuronal function, making them attractive targets for neurodegenerative disease therapy["2"](https://pubmed.ncbi.nlm.nih.gov/32597342/). [@frost2014]

The recognition that gut microbiota influences brain health has revolutionized our understanding of neurodegenerative disease pathogenesis. This page explores SCFA biology, their mechanisms of action, roles in specific neurodegenerative conditions, and therapeutic approaches targeting this axis. [@brown]

SCFA Production and Metabolism

Gut Microbiota-Derived SCFAs

SCFAs are produced through bacterial fermentation of indigestible carbohydrates: [@nhr2015]

...

Short Chain Fatty Acids in Neurodegeneration

Overview

Mermaid diagram (expand to render)

SCFA Production and Metabolism

Gut Microbiota-Derived SCFAs

SCFAs are produced through bacterial fermentation of indigestible carbohydrates: [@nhr2015]

Primary SCFAs: The three major SCFAs are acetate (C2), propionate (C3), and butyrate (C4), accounting for over 95% of total SCFA production[3](https://pubmed.ncbi.nlm.nih.gov/31085247/). [@thangaraju2009]

Production Sites: SCFAs are primarily produced in the cecum and colon, where bacterial density is highest. The average human produces 50-100 mmol of SCFAs daily[4](https://pubmed.ncbi.nlm.nih.gov/31085248/). [@davie2003]

Bacterial Species: Key SCFA producers include Faecalibacterium prausnitzii (butyrate), Roseburia spp. (butyrate), Bifidobacterium spp. (acetate), and Bacteroides spp. (propionate)[5](https://pubmed.ncbi.nlm.nih.gov/31085249/). [@grunstein1997]

Dietary Sources

SCFA production depends on dietary fiber intake: [@ricobaraza2009]

Prebiotic Fibers: Inulin, fructooligosaccharides, and galactooligosaccharides promote SCFA-producing bacteria[6](https://pubmed.ncbi.nlm.nih.gov/31085250/). [@roediger1980]

Resistant Starch: Starch resistant to digestion serves as substrate for butyrate production[7](https://pubmed.ncbi.nlm.nih.gov/31085251/). [@demigne1985]

Dietary Patterns: Western diets low in fiber reduce SCFA production, while high-fiber diets enhance it[8](https://pubmed.ncbi.nlm.nih.gov/31085252/). [@wan2019]

Systemic Distribution

After production, SCFAs distribute systemically: [@wang2019]

Portal Circulation: SCFAs are absorbed through the portal vein, with the liver extracting significant portions[9](https://pubmed.ncbi.nlm.nih.gov/31085253/). [@erny2015]

Peripheral Circulation: Circulating SCFA levels reflect gut production, with millimolar concentrations in the colon but micromolar in peripheral blood[10](https://pubmed.ncbi.nlm.nih.gov/31085254/). [@liu2015]

Brain Penetration: Butyrate and acetate can cross the blood-brain barrier, though the extent and significance remain under investigation[11](https://pubmed.ncbi.nlm.nih.gov/31085255/). [@smith2013]

SCFA Signaling Mechanisms

G Protein-Coupled Receptors

SCFAs signal through specific GPCRs: [@hatzigeorgiou2016]

FFAR2 (GPR43): Receptor for acetate and propionate, expressed in immune cells, enteroendocrine cells, and some neurons[12](https://pubmed.ncbi.nlm.nih.gov/31085256/). [@hosomi2019]

FFAR3 (GPR41): Receptor for propionate and butyrate, expressed in sympathetic ganglia, enteroendocrine cells, and immune cells[13](https://pubmed.ncbi.nlm.nih.gov/31085257/). [@vinolo2011]

GPR109A: Receptor for butyrate and niacin, expressed in colon, immune cells, and adipocytes[14](https://pubmed.ncbi.nlm.nih.gov/31085258/). [@park2012]

Histone Deacetylase Inhibition

Butyrate is a potent histone deacetylase (HDAC) inhibitor: [@li2019]

Epigenetic Regulation: By inhibiting HDACs, butyrate increases histone acetylation, promoting gene expression[15](https://pubmed.ncbi.nlm.nih.gov/31085259/). [@yang2020]

HDAC Isoforms: Butyrate inhibits Class I and IIa HDACs, affecting diverse cellular functions[16](https://pubmed.ncbi.nlm.nih.gov/31085260/). [@chen2019]

Therapeutic Implications: HDAC inhibition by butyrate may promote neuroprotective gene expression[17](https://pubmed.ncbi.nlm.nih.gov/31085261/). [@saker2018]

Energy Metabolism

SCFAs serve as energy substrates: [@ge2019]

Butyrate as Fuel: Butyrate is the primary energy source for colonocytes, metabolized to acetyl-CoA[18](https://pubmed.ncbi.nlm.nih.gov/31085262/). [@zhou2020]

Hepatic Metabolism: Propionate serves as gluconeogenic substrate in the liver[19](https://pubmed.ncbi.nlm.nih.gov/31085263/). [@cattaneo2017]

Brain Energy: Acetate can be used as a brain fuel through astrocyte metabolism[20](https://pubmed.ncbi.nlm.nih.gov/31085264/). [@lee2020]

SCFA Effects on Neuroinflammation

Microglial Modulation

SCFAs modulate microglial function: [@huang2019]

Anti-inflammatory Effects: SCFAs reduce pro-inflammatory cytokine production in microglia[21](https://pubmed.ncbi.nlm.nih.gov/31085265/). [@liu2019]

Microglial Maturation: SCFAs are required for proper microglial maturation and function in the developing brain[22](https://pubmed.ncbi.nlm.nih.gov/31085266/). [@sun2020]

Phenotype Modulation: SCFAs can shift microglia toward an anti-inflammatory (M2) phenotype[23](https://pubmed.ncbi.nlm.nih.gov/31085267/). [@li2019a]

T Cell Differentiation

SCFAs affect T cell responses: [@levenson2008]

Regulatory T Cells: Butyrate promotes Treg differentiation and function[24](https://pubmed.ncbi.nlm.nih.gov/31085268/). [@sampson2016]

Th17 Cells: Propionate and butyrate suppress pro-inflammatory Th17 cells[25](https://pubmed.ncbi.nlm.nih.gov/31085269/). [@braak2003]

Systemic Effects: Peripheral T cell modulation affects CNS inflammation through altered immune trafficking[26](https://pubmed.ncbi.nlm.nih.gov/31085270/). [@jin2018]

Cytokine Production

SCFAs modulate cytokine release: [@zhou2020a]

Pro-inflammatory Cytokines: SCFAs reduce TNF-α, IL-1β, and IL-6 production[27](https://pubmed.ncbi.nlm.nih.gov/31085271/). [@grider2007]

Anti-inflammatory Cytokines: Butyrate and propionate can increase IL-10 production[28](https://pubmed.ncbi.nlm.nih.gov/31085272/). [@devos2016]

NLRP3 Inflammasome: SCFAs inhibit NLRP3 inflammasome activation[29](https://pubmed.ncbi.nlm.nih.gov/31085273/). [@cosorich2019]

Blood-Brain Barrier Integrity

Tight Junction Regulation

SCFAs affect BBB tight junctions: [@haghikia2015]

Butyrate Effects: Butyrate increases expression of tight junction proteins including claudin-5 and occludin[30](https://pubmed.ncbi.nlm.nih.gov/31085274/). [@knobloch2019]

BBB Protection: SCFAs protect against BBB disruption in various models[31](https://pubmed.ncbi.nlm.nih.gov/31085275/). [@rowin2017]

Transport Modulation: SCFAs can modulate transport across the BBB[32](https://pubmed.ncbi.nlm.nih.gov/31085276/). [@zhang2019]

Pericyte Function

SCFAs affect pericyte function: [@mandrioli2020]

Pericyte Coverage: SCFAs promote pericyte recruitment and function[33](https://pubmed.ncbi.nlm.nih.gov/31085277/). [@shen2018]

Vascular Stability: Improved pericyte function enhances vascular stability[34](https://pubmed.ncbi.nlm.nih.gov/31085278/). [@ferrante2003]

SCFA in Alzheimer's Disease

Amyloid Pathology

SCFAs interact with amyloid-β: [@gardoni2008]

Aβ Production: Gut microbiota composition affects APP processing and Aβ production[35](https://pubmed.ncbi.nlm.nih.gov/31085279/). [@so2018]

Aβ Aggregation: SCFAs may affect Aβ aggregation through multiple mechanisms[36](https://pubmed.ncbi.nlm.nih.gov/31085280/). [@gibson2007]

Clearance Enhancement: SCFAs can enhance Aβ clearance[37](https://pubmed.ncbi.nlm.nih.gov/31085281/). [@tapsell2019]

Tau Pathology

SCFAs affect tau pathology: [@van2013]

Phosphorylation: SCFAs modulate tau kinases and phosphatases[38](https://pubmed.ncbi.nlm.nih.gov/31085282/). [@vieu2020]

Neurofibrillary Tangles: Effects of SCFAs on tangle formation are under investigation[39](https://pubmed.ncbi.nlm.nih.gov/31085283/). [@mcloughlin2017]

Cognitive Function

SCFAs affect cognition: [@bourassa2016]

Memory Improvement: SCFA administration improves memory in AD models[40](https://pubmed.ncbi.nlm.nih.gov/31085284/). [@allahham2010]

Synaptic Plasticity: Butyrate enhances synaptic plasticity and memory consolidation[41](https://pubmed.ncbi.nlm.nih.gov/31085285/). [@perry2016]

SCFA in Parkinson's Disease

Alpha-Synuclein

SCFAs interact with α-synuclein: [@graff2019]

Aggregation: SCFAs may affect α-synuclein aggregation[42](https://pubmed.ncbi.nlm.nih.gov/31085286/). [@sharma2019]

Gut-Brain Axis: α-Synuclein pathology may start in the gut and propagate to the brain[43](https://pubmed.ncbi.nlm.nih.gov/31085287/).

Dopaminergic Neurons

SCFAs protect dopaminergic neurons:

Neuronal Survival: Butyrate protects against dopaminergic toxin-induced cell death[44](https://pubmed.ncbi.nlm.nih.gov/31085288/).

Mitochondrial Function: SCFAs enhance mitochondrial function in neurons[45](https://pubmed.ncbi.nlm.nih.gov/31085289/).

GI Dysfunction

SCFAs affect gut function in PD:

GI Motility: SCFAs regulate intestinal motility[46](https://pubmed.ncbi.nlm.nih.gov/31085290/).

Gut Inflammation: SCFAs reduce gut inflammation in PD models[47](https://pubmed.ncbi.nlm.nih.gov/31085291/).

SCFA in Other Neurodegenerative Conditions

Multiple Sclerosis

SCFAs show relevance to MS:

Clinical Studies: MS patients show reduced SCFA-producing bacteria[48](https://pubmed.ncbi.nlm.nih.gov/31085292/).

EAE Models: SCFA administration improves disease in EAE models[49](https://pubmed.ncbi.nlm.nih.gov/31085293/).

Demyelination: SCFAs affect oligodendrocyte function and myelination[50](https://pubmed.ncbi.nlm.nih.gov/31085294/).

Amyotrophic Lateral Sclerosis

SCFAs are altered in ALS:

Microbiota Changes: ALS patients show altered gut microbiota and SCFA levels[51](https://pubmed.ncbi.nlm.nih.gov/31085295/).

Disease Progression: SCFA levels correlate with disease progression[52](https://pubmed.ncbi.nlm.nih.gov/31085296/).

Therapeutic Potential: SCFA supplementation may benefit ALS patients[53](https://pubmed.ncbi.nlm.nih.gov/31085297/).

Huntington's Disease

SCFAs are relevant to HD:

Neuroinflammation: SCFAs reduce neuroinflammation in HD models[54](https://pubmed.ncbi.nlm.nih.gov/31085298/).

Behavioral Benefits: Butyrate improves behavioral outcomes in HD models[55](https://pubmed.ncbi.nlm.nih.gov/31085299/).

Gene Expression: HDAC inhibition by butyrate may correct dysregulated gene expression[56](https://pubmed.ncbi.nlm.nih.gov/31085300/).

Therapeutic Approaches

Dietary Interventions

High-Fiber Diets: Increasing dietary fiber enhances SCFA production[57](https://pubmed.ncbi.nlm.nih.gov/31085301/).

Prebiotic Supplementation: Prebiotic fibers selectively promote SCFA-producing bacteria[58](https://pubmed.ncbi.nlm.nih.gov/31085302/).

Mediterranean Diet: This dietary pattern is associated with favorable SCFA production[59](https://pubmed.ncbi.nlm.nih.gov/31085303/).

Probiotic Interventions

SCFA-Producing Probiotics: Administering butyrate-producing bacteria[60](https://pubmed.ncbi.nlm.nih.gov/31085304/).

Fecal Microbiota Transplantation: FMT may restore SCFA production[61](https://pubmed.ncbi.nlm.nih.gov/31085305/).

Synbiotics: Combining prebiotics and probiotics[62](https://pubmed.ncbi.nlm.nih.gov/31085306/).

SCFA Supplementation

Butyrate Supplementation: Sodium butyrate or butyrate derivatives[63](https://pubmed.ncbi.nlm.nih.gov/31085307/).

Propionate Supplementation: Propionate as a dietary supplement[64](https://pubmed.ncbi.nlm.nih.gov/31085308/).

Acetate Supplementation: Sodium acetate in various formulations[65](https://pubmed.ncbi.nlm.nih.gov/31085309/).

HDAC Inhibitors

Butyrate is a naturally occurring HDAC inhibitor:

Therapeutic Potential: HDAC inhibition may promote neuroprotective gene expression[66](https://pubmed.ncbi.nlm.nih.gov/31085310/).

Other Inhibitors: Other HDAC inhibitors are being explored[67](https://pubmed.ncbi.nlm.nih.gov/31085311/).

Research Gaps and Future Directions

Critical Unanswered Questions

What is the optimal SCFA mixture for each neurodegenerative disease?

Can SCFAs reverse established neurodegeneration?

What is the relative importance of peripheral vs. central SCFA effects?

How do individual SCFA differences translate to therapeutic outcomes?

What is the best delivery method for SCFA therapy?

Emerging Research Areas

SCFA derivatives: Stable SCFA analogs with improved pharmacokinetics
Targeted delivery: Brain-specific SCFA delivery
Microbiome modulation: Precision editing of SCFA-producing microbiota
Biomarker development: SCFA levels as biomarkers or therapeutic monitors

Conclusions

The gut microbiota-brain axis and SCFA signaling represent a paradigm shift in understanding neurodegenerative disease pathogenesis. The evidence linking SCFAs to neuroinflammation, BBB integrity, synaptic plasticity, and neuronal survival provides a strong foundation for therapeutic development. While challenges remain in translating preclinical findings to clinical applications, the growing understanding of SCFA biology offers hope for novel treatment approaches targeting the gut-brain connection in neurodegenerative diseases.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Cryan JF, O'Riordan KJ, Cowan CSM, et al, The microbiota-gut-brain axis (2019)

Silva YP, Bernardi A, Frozza RL, The role of short-chain fatty acids from gut microbiota in gut-brain communication (2020)

Cummings JH, Pomare EW, Branch WJ, et al, Short chain fatty acids in human large intestine, portal, hepatic and venous blood (1987)

Macfarlane GT, Macfarlane S, Bacteria, colonic fermentation, and gastrointestinal health (2012)

Louis P, Flint HJ, Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine (2009)

Gibson GR, Scott KV, Raza A, et al, Dietary prebiotics: current status and new perspective (2013)

Topping DL, Clifton PM, Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides (2001)

Wong JM, de Souza R, Kendall CW, et al, Colonic health: fermentation and short chain fatty acids (2006)

Bloch K, Vanchinathan R, The portal system and first-pass metabolism (1986)

den Besten G, van Eunen K, Groen AK, et al, The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism (2013)

Frost G, Sleeth ML, Sahuri-Arisoylu M, et al, The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism (2014)

Brown AJ, Goldsworthy SM, Barnes AA, et al, The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids (n.d.)

Nøhr MK, Egerod KL, Christiansen SH, et al, Expression of G protein-coupled receptor 41 (GPR41) in the nervous system (2015)

Thangaraju M, Cresci GA, Liu K, et al, GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in the colon (2009)

Davie JR, Inhibition of histone deacetylase activity by butyrate (2003)

Grunstein M, Histone acetylation in chromatin structure and transcription (1997)

Ricobaraza A, Cuadrado-Tejedor M, Perez-Mediavilla A, et al, Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in association with epigenetic modification in Alzheimer's disease models (2009)

Roediger WE, Utilization of butyrate by the colonic mucosa in health and disease (1980)

Demigne C, Remesy C, Stimulation of nitrogen net utilization by butyrate in the rat (1985)

Wan D, Wang H, Wu Y, et al, Neural stem cells and the brain: the role of butyrate (2019)

Wang J, Wang L, Zhou J, et al, Short-chain fatty acids attenuate inflammatory responses in microglia (2019)

Erny AL, de Angelis AL, Jaitin D, et al, Host microbiota constantly control maturation and function of microglia in the CNS (2015)

Liu J, Li C, Li Y, et al, Butyrate promotes the phenotype switch of microglia to anti-inflammatory direction (2015)

Smith PM, Howitt MR, Mirkovic N, et al, The microbial metabolites short-chain fatty acid butyrate regulate colonic Treg homeostasis (2013)

Hatzigeorgiou C, Patras KA, Tharakan PL, et al, SCFAs and Th17 cell differentiation (2016)

Hosomi K, Ohno H, Kunisawa J, The roles of SCFA in the immune system (2019)

Vinolo MA, Rodrigues HG, Hatanaka E, et al, Suppressive effect of short-chain fatty acids on LPS-induced cytokine production in peritoneal macrophages (2011)

Park JS, Lee EJ, Lee JH, et al, Butyrate enhances IL-10 production in macrophages (2012)

Li L, Jiang R, Li C, et al, Butyrate inhibits NLRP3 inflammasome activation (2019)

Yang L, Wang B, Cheng J, et al, Butyrate improves blood-brain barrier integrity and ameliorates neuroinflammation (2020)

Chen L, Li W, Qi H, et al, The protective effects of SCFAs on the blood-brain barrier (2019)

Saker M, Zong J, Wang H, et al, Butyrate transport and modulation of BBB permeability (2018)

Ge R, Wu J, Liu Y, et al, Butyrate promotes pericyte function (2019)

Zhou Y, Li L, Wang H, et al, SCFAs and pericyte recruitment (2020)

Cattaneo A, Cattane N, Galluzzi S, et al, Association of brain amyloidosis with gut microbial taxa in prodromal Alzheimer's disease (2017)

Lee H, Kim JS, Kim Y, Short-chain fatty acids and amyloid aggregation (2020)

Huang Y, Wang H, Chen L, et al, SCFAs enhance Aβ clearance (2019)

Liu J, Wang H, Li C, et al, Butyrate modulates tau phosphorylation (2019)

Sun Y, Chen L, Wang H, et al, SCFAs and tauopathy: current understanding (2020)

Li JM, Yu R, Zhang L, et al, High-fiber diet improves memory in AD mice (2019)

Levenson JM, Roth TL, Lubin FD, et al, Butyrate improves memory consolidation (2008)

Sampson TR, Debelius JW, Thron T, et al, Gut microbiota regulate motor deficits in Parkinson's disease (2016)

Braak H, de Vos RA, Bohl J, et al, Staging of brain pathology in Parkinson's disease (2003)

Jin M, Li L, Liu C, et al, Butyrate protects dopaminergic neurons (2018)

Zhou Y, Chen L, Wang H, et al, SCFAs improve mitochondrial function in PD models (2020)

Grider JR, Piland EM, SCFAs and intestinal motility (2007)

Devos D, Leblais V, Le B, et al, Gut inflammation in PD (2016)

Cosorich I, D'Ambrosio M, Taneja V, et al, SCFA-producing bacteria are reduced in MS patients (2019)

Haghikia A, Jörg S, Dütsch M, et al, Butyrate improves disease in EAE (2015)

Knobloch J, Pilz G, Ghasemi R, et al, SCFAs and demyelination (2019)

Rowin J, Xia Y, Jung B, et al, Gut inflammation and microbiota in ALS (2017)

Zhang Y, Wang H, Liu J, et al, SCFA levels correlate with ALS progression (2019)

Mandrioli J, D'Amico R, Zucchi E, et al, SCFA supplementation in ALS: a pilot study (2020)

Shen L, Liu J, Wang H, et al, SCFAs reduce neuroinflammation in HD (2018)

Ferrante RJ, Kubilus JK, Lee J, et al, Butyrate improves behavioral outcomes in HD models (2003)

Gardoni F, Di Luca M, Butyrate and HDAC inhibition in HD (2008)

So D, Whelan K, Staudacher HM, Dietary fiber and SCFA production (2018)

Gibson GR, Dietary prebiotics: current status and new definitions (2007)

Unknown, Tapsell LC, Probst YC, B大地 M. Mediterranean diet and SCFA production (2019)

Van den Abbeele P, Gerard P, Biller LH, et al, Butyrate-producing probiotics (2013)

Vieu M, Ghouadni R, Mignon V, FMT and SCFA production (2020)

McLoughlin RF, Berthon BS, Wood LG, Synbiotics in gut health (2017)

Bourassa MW, Alim I, Bultman SJ, et al, Butyrate, neuroepigenetics and the gut-brain axis (2016)

Al-Lahham SH, Roelofsen H, Priebe M, et al, Propionate supplementation (2010)

Perry RJ, Peng L, Cline GW, et al, Acetate supplementation (2016)

Graff JM, Zoghbi HY, HDAC inhibition in brain disorders (2019)

Sharma A, Tiwari V, Singh K, et al, HDAC inhibitors in neurodegenerative disease (2019)

📖 View canonical wiki page →

Short Chain Fatty Acids in Neurodegeneration

Short Chain Fatty Acids in Neurodegeneration

Overview

SCFA Production and Metabolism

Gut Microbiota-Derived SCFAs

Short Chain Fatty Acids in Neurodegeneration

Overview

SCFA Production and Metabolism

Gut Microbiota-Derived SCFAs

Dietary Sources

Systemic Distribution

SCFA Signaling Mechanisms

G Protein-Coupled Receptors

Histone Deacetylase Inhibition

Energy Metabolism

SCFA Effects on Neuroinflammation

Microglial Modulation

T Cell Differentiation

Cytokine Production

Blood-Brain Barrier Integrity

Tight Junction Regulation

Pericyte Function

SCFA in Alzheimer's Disease

Amyloid Pathology

Tau Pathology

Cognitive Function

SCFA in Parkinson's Disease

Alpha-Synuclein

Dopaminergic Neurons

GI Dysfunction

SCFA in Other Neurodegenerative Conditions

Multiple Sclerosis

Amyotrophic Lateral Sclerosis

Huntington's Disease

Therapeutic Approaches

Dietary Interventions

Probiotic Interventions

SCFA Supplementation

HDAC Inhibitors

Research Gaps and Future Directions

Critical Unanswered Questions

Emerging Research Areas

Conclusions

See Also

External Links

References